Hypertensive ventricular remodeling is a common cause of heart failure. However, the molecular mechanisms regulating ventricular remodeling remain poorly understood.
RESULTS: ATF3 expression increased in murine hypertensive heart and human hypertrophic heart. Cardiac fibroblast cells are the primary cell type expressing high ATF3 levels in response to hypertensive stimuli. ATF3 knockout (ATF3KO) markedly exaggerated hypertensive ventricular remodeling, a state rescued by lentivirus-mediated/miRNA-aided cardiac fibroblast-selective ATF3 overexpression. Conversely, conditional cardiac fibroblast cell-specific ATF3 transgenic overexpression significantly ameliorated ventricular remodeling and heart failure. We identified Map2K3 as a novel ATF3 target. ATF3 binds with the Map2K3 promoter, recruiting HDAC1, resulting in Map2K3 gene-associated histone deacetylation, thereby inhibiting Map2K3 expression. Genetic Map2K3 knockdown rescued the profibrotic/hypertrophic phenotype in ATF3KO cells. Last, we demonstrated that p38 is the downstream molecule of Map2K3 mediating the profibrotic/hypertrophic effects in ATF3KO animals. Inhibition of p38 signaling reduced transforming growth factor-β signaling-related profibrotic and hypertrophic gene expression, and blocked exaggerated cardiac remodeling in ATF3KO cells.
CONCLUSIONS:
Our study provides the first evidence that ATF3 upregulation in cardiac fibroblasts in response to hypertensive stimuli protects the heart by suppressing Map2K3 expression and subsequent p38-transforming growth factor-β signaling. These results suggest that positive modulation of cardiac fibroblast ATF3 may represent a novel therapeutic approach against hypertensive cardiac remodeling.
Cardiac Fibroblast-Specific Activating Transcription Factor 3 Protects Against Heart
Failure by Suppressing MAP2K3-p38 Signaling D espite technological and pharmaceutical advances, heart failure remains a leading cause of mortality and morbidity. Hypertensive ventricular remodeling is a common cause of heart failure. Two key aspects of hypertensive ventricular remodeling are cardiac hypertrophy and fibrosis, caused by mechanical stress from blood pressure elevation, neurohormonal alteration, growth factors, and cytokines. 1 Short-term hypertrophy diminishes wall stress, and is adaptive, but persistent hypertrophy is detrimental. Fibrosis (surplus extracellular matrix) promotes both contractile dysfunction and rhythm disturbances. 2 Therefore, suppressing hypertensive ventricular remodeling may impede heart failure progression.
The clinical management of pathological ventricular remodeling includes select pharmacological agents. Targeting the renin-angiotensin-aldosterone system or β-adrenergic receptor in both animal models and humans attenuates hypertrophy and fibrosis, and extends the life span of patients with heart failure. 3 Ca 2+ channel blockers reverse cardiac hypertrophy in some animal models. 4 Atop managing hypertension, these agents reduce pathological ventricular remodeling by limiting neuroendocrine circuitry and intracellular transduction pathways, the molecular basis of both cardiac hypertrophy and fibrosis. It is disappointing that the overall efficacy of these agents remains limited. Although some patients are simply refractory to therapy, cardiovascular disease may progress even in agent-responsive patients. 5, 6 Clearly, a deeper understanding of the responsible signaling pathways is necessary to derive improved treatment options.
Regulation of gene expression is central for heart development and disease. Cardiac hypertrophy can be viewed as a pro-and antihypertrophic gene regulatory disorder. Context-specific regulation of gene expression is achieved largely by transcription factors (TFs). Cardiac TFs have been reported to precisely control a cardiac gene program involved in the generation of cardiac hypertrophy and fibrosis, such as GATA4, nuclear factoractivated T cell, and myocyte enhancer factor 2. [7] [8] [9] [10] Because TFs orchestrate the numerous gene expressions in the adult heart in response to hypertrophic stimulation, cardiac TFs may be promising therapeutic targets. The development of drug molecules or decoy oligodeoxynucleotides that will selectively suppress the activity of prohypertrophic TFs may be of therapeutic interest. Augmenting the activity of antihypertrophic TFs is also a promising approach. Identifying the endogenous protective TFs counterbalancing the prohypertrophic TFs may be crucial in designing novel therapeutics against hypertensive remodeling and heart failure.
Utilizing a discovery-driven/unbiased approach, we have identified ATF3 (a member of the cAMP response element binding family of basic leucine zipper TF 11 ) to be a cardiac fibroblast-enriched transcription factor that is cardioprotective against hypertensive remodeling, via suppression of Map2K3 expression and p38 mitogenactivated protein kinase (p38 MAPK) signaling. Our results suggest positive modulation of cardiac fibroblast ATF3, a hub of the cellular adaptive-response network, may represent a novel therapeutic approach against hypertensive cardiac remodeling.
METHODS
Relevant citations have been provided for previously published protocols used in the current study.
Whole-body ATF3-knockout mice were kindly provided by Dr Hongliang Li (generation/characterization of this mouse strain described previously 12 ). We established a conditional cardiac fibroblast-specific ATF3-transgenetic mouse (ATF3 fl/ fl TG) and miRNA-aided/lentivirus-mediated noncardiac myocyte ATF3 overexpression model in our laboratory. Detailed methods are provided in the online-only Data Supplement. All animals were maintained under pathogen-free conditions. All experiments were performed using 10-to 12-week-old male mice. In the angiotensin II (Ang II) infusion model, mice were infused with Ang II subcutaneously (1000 ng·kg
) for 7 or 28 days with ALZET miniosmotic pumps (DURECT). 13, 14 Blood pressure was measured daily via the tail-cuff method. In the pressure-overload model, transverse aortic constriction (TAC) or sham operation was performed. 15 Cardiac function was evaluated by the Vevo 770 high-resolution microimaging system (Visualsonic). All animal handling complied with animal welfare regulations of Capital Medical University. The Animal Subjects Committee of Capital Medical University approved the animal study protocol.
Detailed methodology for all protocols used in this study, including immunofluorescence, in situ hybridization, quantitative real-time polymerase chain reaction (qRT-PCR), RNA sequencing, microarray, chromatin immunoprecipitation (ChIP) assay, ChIP sequencing, immunoprecipitation, immunoblotting, cardiac fibroblasts and cardiomyocytes culturing, cell sorting,
Clinical Perspective
What Is New?
• We have identified both a novel transcription factor (activating transcription factor 3) and the mechanism by which it protects against the development of heart remodeling.
• Activating transcription factor 3 protected against cardiac hypertensive remodeling, heart failure, and fibrosis, via suppression of Map2K3 expression and p38 mitogen-activated protein kinase signaling.
What Are the Clinical Implications?
• Identifying molecules mimicking endogenous ligands or inhibiting miRNA that downregulate activating transcription factor 3 expression may represent a novel therapeutic approach against hypertensive cardiac remodeling.
Map2K3 knockdown, ATF3 overexpression, and cytokines measurement, is provided in online-only Data Supplement Methods.
Statistical Analysis
Data are presented as means±standard error of the mean of n independent experiments. Normality analysis was performed before any testing, via the Shapiro-Wilk test. Differences were evaluated using the unpaired Student t test between 2 groups. One-way analysis of variance was conducted followed by Bonferroni post hoc test for comparisons between >2 groups. The nonnormal distributed data were analyzed using nonparametric testing (Mann-Whitney U test for 2 groups and KruskalWallis H test for >2 groups). Differences between groups over time were evaluated by using repeated measures analysis of variance. The transcriptome data were analyzed by multiple testing. P values of <0.05 were considered statistically significant. Statistical analysis was performed using GraphPad Prism 4.0 (GraphPad Software Inc) and SPSS 13.0 (SPSS Inc) software.
RESULTS

ATF3 Expression Is Consistently Increased in Cardiac Tissues From Hypertensive Animals and Patients With Heart Failure
To identify the TFs regulating hypertensive cardiac remodeling in a nonbiased fashion, transcriptome analysis was performed in heart samples from 2 different hypertensive cardiac remodeling models: Ang II infusion (7 or 28 days, respective time points when significant ventricular remodeling has not and has developed, using RNA sequencing) and TAC (28 days, using microarrray Figure 1A and 1B and online-only Data Supplement Table I ). Further analysis revealed that 22 differentially expressed TF genes overlap between 7 and 28 days post-Ang II infusion, and 7 differentially expressed TF genes overlap between Ang II infusion-induced and TACinduced ventricular remodeling ( Figure 1C ). Among the differentially expressed and overlapping TF genes in these 3 groups, we identified ATF3 as the gene most consistently and significantly upregulated. Consistent with transcriptome data, both ATF3 mRNA and protein levels were significantly increased in both the Ang II-infused and pressure-overloaded heart ( Figure 1D through 1G). Protein-protein interaction network predicted that ATF3 interacts with 48 important proteins (online-only Data Supplement Figure IA) , including other transcriptional complexes involved in immune response (Rela, Jun, Junb, Jund, Fos), fibrosis (smad2/3), and apoptosis (p53, ATF4, ATF2).
To confirm the translational value of our animal model results, we determined whether ATF3 expression is altered in human cardiac tissue. ATF3 protein expression was significantly increased in hypertrophic cardiomyopathy (HCM) patient heart samples in comparison with control ( Figure 1H ). Taken together, these results strongly suggest ATF3 may play a regulatory role in hypertensive ventricular remodeling.
Cardiac Fibroblasts Are the Primary Cellular Type Expressing ATF3 in Response to Stimuli
It is increasingly recognized that molecules expressed by different heart cell types may differentially regulate global cardiac function1. 16 We next determined the cellular origin of ATF3 expression in the hypertensive heart. In situ hybridization performed on sections of saline or Ang II-infused hearts revealed that ATF3 staining was very weak in saline-treated animals, intensifying after Ang II infusion ( Figure 1I ). It is important to note that abundant ATF3 staining was noted in the cardiac interstitium, but not within cardiomyocytes or vascular cells. Focusing on the cardiac interstitium, we costained tissue sections with antibodies against ATF3 and DDR2 or Col1a1 (cardiac fibroblasts) or CD68 (macrophages). Double staining revealed an intense ATF3 signal in fibroblasts (DDR2 + ,Col1a1 + ), but not in macrophages (CD68 + ) ( Figure 1I and online-only Data Supplement Figure IB) . ATF3 signal in a whole heart section was presented (online-only Data Supplement Figure IC) 13 Subsequent qRT-PCR demonstrated low ATF3 expression in all cardiac cell populations in saline-treated animals. Ang II infusion had no significant effect on ATF3 expression in cardiomyocytes and endothelium, modestly increased ATF3 expression in macrophages, and markedly increased ATF3 expression in cardiac fibroblasts ( Figure 1J ). ATF3 protein was tested in cardiac fibroblasts. In comparison with cardiac fibroblasts of control mice, ATF3 protein expression significantly increased in cardiac fibroblasts isolated from mice after Ang II infusion or TAC ( Figure 1K ). A through C, Global gene expression analysis was performed in hearts from murine models (Ang II infusion for 0, 7, or 28 days; TAC or sham operation for 28 days). Comparative transcriptome profiling was performed in heart tissue, for the Ang II infusion model using the RNA-seq approach and for the TAC model using microarray approach. By comparing DEGs from 3 groups (Ang II day 7 versus day 0, Ang II day 28 versus day 0, TAC versus sham operation) with candidate 1100 TFs from TRANSFAC database, 41, 29, and 42 differentially expressed TFs were identified, respectively. A clustered heat map of expression values for differentially expressed TFs is shown. Asterisk (*) indicates 22 TFs continually changing during Ang II infusion for 7 and 28 days. Pound sign ( # ) indicates 7 TFs with common alteration during Ang II infusion and TAC for 28 days. D and E, Cardiac ATF3 mRNA expression was evaluated by qRT-PCR during different time points of Ang II infusion or TAC (n=5 per group). F and G, ATF3 protein expression was evaluated by Western blot in hearts after Ang II infusion or TAC. *P<0.05 versus saline or sham operation. H, Cardiac ATF3 protein expression in a healthy heart donor and hypertrophic cardiomyopathic patient was evaluated by Western blot. *P<0.05 versus normal heart. I, In situ hybridization analysis demonstrates no ATF3 signal in vascular endothelium or cardiomyocytes (brown arrows). ATF3 signal was markedly detected in cardiac fibroblasts and minimally detected in infiltrated macrophages after Ang II infusion (black arrows). Bars=50 μm. J, After 7 days of saline or Ang II infusion, hearts were digested and sorted into macrophages Having demonstrated that ATF3 is significantly upregulated in cardiac fibroblast during heart failure development, we next determined whether ATF3 upregulation contributes to or protects against ventricular remodeling. We used 4 separate approaches to obtain the most conclusive evidence.
First, we used a loss-of-function approach. Whole body ATF3 knockout (ATF3KO) and wild-type (WT) mice were subjected to Ang II infusion. Ang II infusion induced a similar increase in blood pressure in WT and ATF3KO mice ( Figure 2A) , with significantly increased collagen deposition in ATF3KO mice in comparison with WT (Figure 2B ). ATF3KO mice also exhibited increased α-smooth muscle actin (α-SMA, a marker of myofibroblast-positive cells) protein expression, collagen I, and transforming growth factor-β (TGF-β) mRNA ( Figure 2C through 2E). There was no difference in MYH11-positive vascular smooth muscle cells from WT versus ATF3KO heart sections, which suggested increased α-SMA expression because of the presence of myofibroblast not new vessel formation (online-only Data Supplement Figure IIA ). ATF3KO mouse hearts gained significantly more weight after Ang II infusion, with increased cardiomyocyte hypertrophy ( Figure 2F and 2G). The mRNA levels of Myh7 and ANP (hypertrophy-associated genes) were increased in ATF3KO mice after Ang II infusion ( Figure 2H ). These data suggest that ATF3 upregulation during heart failure development is a self-protective mechanism against hypertensive ventricular remodeling.
Second, we used a viral-mediated rescue approach. To avoid ATF3 overexpression in cardiomyocytes, we established a miRNA-aided/lentivirus (LV)-mediated system, as recently reported. 18, 19 As mir-1a and mir-133a are the most abundant miRNA in cardiac myocytes, 20 we designed a ATF3 expression cassette driven by a Ubi promoter containing 2 tandem copies of a 22-bp complementary target sequence for the mir-1a-3p and mir133a-3p strands at the 3ʹ end of the vector cassette (LV-ATF3-mir1/133TS, Figure 3A ). LV-control-mir1/133TS served as a control LV vector. We first transfected primary cardiac myocytes and fibroblast isolated from ATF3KO animals with LV-ATF3-mir1/133TS and LV-control-mir1/133TS (50 PFU/cell). ATF3 expression was markedly increased in LV-ATF3-mir1/133TS transfected cardiac fibroblast, but only modestly increased in cardiomyocytes ( Figure 3B ). The LV vectors were administered via tail vein injection to the ATF3KO mice (dose 3×10 8 PFU per mouse). The efficiency of viral transduction in heart was evaluated in mice injected with saline, LV-Conmir1/133TS, LV-ATF3-mir1/133TS by flow cytometry. GFP + cells accounted for ≈5% to 10% of total cells in heart with viral transduction (online-only Data Supplement Figure IIIA and IIIB). To elevate the specificity of the approach, we isolated the GFP + cardiac fibroblasts and GFP + cardiomyocytes from ATF3KO mice injected with LV-Con-mir1/133TS or LV-ATF3-mir1/133TS (onlineonly Data Supplement Figure IIIA and IIIC). ATF3 proteins were significantly increased in cardiac fibroblast, but only slightly increased in cardiomyocytes in mice with LV-ATF3-mir1/133TS (online-only Data Supplement Figure IIID ). ATF3KO mice were administrated with LVcontrol, LV-Con-mir1/133TS, or LV-ATF3-mir1/133TS followed by Ang II infusion for 7 days. After 7 days, the heart tissues were harvested for histopathology and isolation of cardiac fibroblasts. ATF3 expression was significantly increased in the hearts of LV-ATF3-mir1/133TS transduced ATF3KO mice ( Figure 3C ). Immunostaining revealed ATF3 expression in col1a2-positive fibroblasts in ATF3KO mice transduced with LV-ATF3-mir1/133TS, but not in α-actinin-positive cardiomyocytes. There is no ATF3 expression in mice transduced with LVCon-mir1/133TS ( Figure 3D ). With the use of LV-ATF3-mir1/133TS transduction, ATF3 expression in ATF3KO mice reached 60% of WT mouse expression treated with LV-Con-mir1/133TS followed by Ang II infusion for 7 days (online-only Data Supplement Figure IIIE) . It is important to note that, in comparison with LV-control or LV-Con-mir1/133TS group, transduction with LV-ATF3-mir1/133TS inhibited cardiac fibrosis and hypertrophy in ATF3KO mice after Ang II infusion ( Figure 3E through 3G). Taken together, these data demonstrated that the ATF3KO mouse phenotype was successfully rescued by miRNA-aided/LV-mediated cardiac fibroblast ATF3 overexpression.
Third, we used a gain-of-function approach. To obtain the most conclusive data supporting a notion that increased ATF3 expression in cardiac fibroblast is cardioprotective, a conditional cardiac fibroblast-specific ATF3-transgenetic mouse model was generated (ATF3 fl/fl TG mice were crossed with inducible fibroblast-specific Cre mice (col1a2-Cre/ERT). Tamoxifen was administered intraperitoneally to activate gene expression. To assess the transgenic leakiness, we determined Col1a2 and ATF3 expression in heart, liver, lung, kidney, spleen, and vessels. High-level Col1a2 expression was only observed in heart and vessel, low-level Col1a2 expression TGCre -mice, ATF3 mRNA expression was significantly increased in cardiac fibroblasts (but not cardiomyocytes) from ATF3 fl/fl TG Cre + mice (online-only Data Supplement Figure IVD) . To identify which cell population is actually expressing the transgene, we tested the ATF3 proteins expression in isolated cardiac fibroblasts, cardiomyocytes, and endothelial cells. The cardiac fibroblast was the only cell type with significantly increased ATF3 expression (online-only Data Supplement Figure  IVE) . Using lineage tracing technique, a previous study demonstrated that >96% Col1a2 + cells were cardiac fibroblasts and not other cardiovascular cell types. 21 We determined the colocation of Col1a2 expression with Col1a1 (cardiac fibroblasts), α-actinin (cardiomyocytes), CD31 (endothelial), SM22 (smooth muscle cells), and Col2a1(valve cells). TGCre + mice subjected to Ang II ( Figure 4A ). Ang II-induced gross and microscopic changes were significantly attenuated in ATF3 fl/fl TGCre + mice; specifically, the heart was grossly smaller, the left ventricle was less dilated, cardiac fibrosis was reduced, and heart weight/body weight ratios were decreased ( Figure 4B through 4D ). In addition, the cardiomyocyte cross-sectional area was significantly smaller (Figure 4E Fourth and finally, a bone marrow (BM) transplantation approach was used. As Ang II infusion modestly increased macrophage ATF3 expression in comparison with saline control (Figure 1J ), we determined whether macrophage A, Schematic representation of ATF3 expression cassette in the LV vectors engineered to inhibit overexpression of exogenous ATF3 or negative control in cardiomyocytes expression mir-1a-3p and mir-133a-3p. B, CM and CF were transfected with indicated LV vector. ATF3 expression was assessed in CM and CF by Western blot. C, ATF3KO mice were injected with LV control, LV-Con-mir1/133TS, or LV-ATF3-mir1/133TS, then followed by Ang II infusion for 7 days. ATF3 expression was assessed in heart by Western blot. D, Representative sections of heart immunostained for GFP, ATF3, and Col1a2 or α-actinin in ATF3KO mice transduced with LV-Con-mir1/133TS or LV-ATF3-mir1/133TS. E, Representative Masson trichrome and WGA-stained sections. Bars=500 μm (Top); 100 μm (Middle); 50 μm (Bottom). 
Map2K3 Is a Novel ATF3 Target Gene Whose Inhibition by ATF3 Is Responsible for ATF3-Mediated Cardioprotection
To explore how ATF3 regulates ventricular remodeling, 2 strategies were used to identify the Map2K3-regulated genes responsible for ATF3-Map2K3 downstream signaling. First, cardiac fibroblasts were isolated from Ang II-infused WT or ATF3KO mice and subjected to transcriptome analysis. RNA-Seq analysis identified 701 upregulated and 468 downregulated DEGs (false discovery rate [FDR]<0.05; fold change>1.2) in ATF3KO cardiac fibroblasts in comparison with WT (online-only Data Supplement Table II) . To confirm the accuracy of RNASeq identification of DEGs, 10 DEGs were randomly selected. qRT-PCR was performed. Nine of 10 DEGs demonstrated completely concordant expression patterns between RNA-Seq and qRT-PCR results (online-only Data Supplement Figure V) . ATF3KO cardiac fibroblast exhibited increased mRNA expression of various profibrotic, hypertrophic, and inflammatory genes (online-only Data Supplement Table III ). Pathway analysis of DEGs revealed Figure 5 . BM-derived cells ATF3 deficiency is not critical for Ang II-induced ventricular remodeling and heart failure. A, Cardiac fibroblasts from ATF3KO mice were transfected with ATF3-overexpressing (Ad-ATF3) or empty (Ad-con) adenovirus for 48 hours, and plus with Ang II for another 6 hours. ATF3 protein expression was determined by Western blot. B, ChIP-seq analysis was performed in cardiac fibroblasts infected with Ad-con or Ad-ATF3 with an ATF3 antibody. Chart demonstrates percentage of peaks within each category. C, ATF3-binded genes identified in the ChIP data set (left circle) were overlaid on genes exhibiting ATF3-dependent expression in RNA-seq analysis (right circle) using WT or ATF3KO fibroblasts. Thirty-one genes were present in both data sets. D, Map of the Map2K3 locus revealing ATF3 binding in CF infected with Ad-con or Ad-ATF3; aligned reads were visualized by Integrated Genomics Viewer 2.0. 24 The signal of the Ad-con or Ad-ATF3 cardiac fibroblasts is represented with yellow or pink peaks, respectively. E, The independent ChIP assay was performed on Ad-con-or Ad-ATF3-infected cardiac fibroblasts to confirm ATF3 binding to the promoter regions of the Map2K3 gene. *P<0.05 versus Ad-con in ATF3 Ab. that upregulated signaling pathways were closely related to hypertensive cardiac remodeling, specifically extracellular matrix deposition (focal adhesion and extracellular matrix-receptor interaction) 22 ; hypertrophy (insulin, MAPK, and mammalian target of rapamycin signaling), 23 and inflammation (cytokine-cytokine receptor interaction and leukocyte transendothlial migration) (online-only Data Supplement Figure VIA and VIB) . Last, Path-Net analysis was performed on 47 significant pathways and their interactions to determine the signaling pathways most likely responsible for ATF3-mediated protection. In this analysis, the MAPK signaling pathway genes exhibited greatest enrichment among the upregulated pathways in ATF3KO cells (online-only Data Supplement Figure VIC) .
Second, cardiac fibroblasts were isolated from AT-F3KO mice, transfected with either ATF3-overexpressing (Ad-ATF3) or empty (Ad-con) adenovirus, and subjected to Ang II stimulation in vitro. After upregulation of ATF3 expression was confirmed in the transfected cells (Figure 6A ), ATF3 ChIP-seq was performed. We identified 727 ATF3 target genes selectively enriched in ATF3-overexpressed cardiac fibroblasts ( Figure 6B ). To narrow the number of ATF3-mediated genes, we performed a 2-tiered bioinformatics analysis: (1) transcriptome differential analysis between WT and ATF3-depleted fibroblasts for genes related to ATF3; and (2) differential ATF3 ChiP sequencing in ATF3-depleted fibroblasts transfected with Ad-con and Ad-ATF3 for ATF3-bound genes. Thirty-one genes exhibiting significant mRNA alteration between WT and ATF3-depleted cardiac fibroblasts were identified to directly bind with ATF3 ( Figure 6C and online-only Data Supplement Table IV) .
Combining the findings from these 2 strategies, we focused on MAPK pathway genes. ChIP-seq analysis revealed a significant ATF3-binding promoter region in the Map2K3 gene ( Figure 6D ). Independent ChIP assays confirmed marked enrichment of Map2K3 over normal IgG following ATF3 overexpression ( Figure 6E ). It is interesting to note that Map2K3 mRNA expression is increased in ATF3KO cardiac fibroblasts, and decreased in Ad-ATF3 transfected cardiac fibroblasts ( Figure 6F through 6H) , suggesting this transcription factor inhibits, rather than stimulates Map2K3 expression. Consistent with these in vitro findings, Map2K3 mRNA ( Figure 6I ) and protein (Figure 6J, lane 1 To establish a causative relationship between Map2K3 upregulation and exacerbated hypertensive cardiac remodeling in ATF3KO animals, we performed several experiments. First, cardiac fibroblasts were isolated and treated with Ang II in vitro. In comparison with control, Ang II induced α-SMA and collagen I expression in cardiac fibroblast to a greater extent in ATF3KO mice ( Figure 7A ). Inhibition of Map2K3 (by a LV expressing a Map2K3 shRNA, LV-Map2K3-shRNA, online-only Data Supplement Figure VIIA and VIIB) significantly attenuated Ang II-induced α-SMA and collagen I expression in ATF3KO cardiac fibroblasts ( Figure 7B ). Cardiac fibroblasts regulate cardiac myocytes via paracrine communication. 25 We next cocultured cardiac myocytes with cardiac fibroblasts isolated from ATF3KO animals, and determined the effect of Map2K3 inhibition on Ang IIinduced cardiac myocyte hypertrophy. Genetic inhibition of Map2K3 with LV-Map2K3-shRNA significantly inhibited Ang II-induced ANP expression and decreased cardiac myocyte size ( Figure 7C and 7D) .
Because our data suggest that ATF3 inhibits Map2K3 gene expression, we investigated the potential mechanism by which ATF3 suppresses Map2K3 transcription. The protein-protein interaction map demonstrated connectivity of ATF3 with histone deacetylases (HDACs) (online-only Data Supplement Figure I ). It is interesting to note that co-immunoprecipitation assays demonstrated that HDAC1 is indeed present in the ATF3-immunoprecipitated complex ( Figure 7E ). Most important, levels of Map2K3 promoter-bound histone acetylation (H4ac) in cardiac fibroblasts were significantly increased in response to Ang II, an effect significantly attenuated by ATF3 overexpression ( Figure 7F ).
p38 MAPK Activation Mediates ATF3 DeficiencyInduced Fibrosis and Hypotrophy
Map2K3 achieves diverse biological function by activating p38 MAPK. Figure 6J demonstrates that the phosphorylation of p38 and its downstream target, MAPK-activated protein kinase 2 (but not JNK or ERK1/2), were significantly increased in cardiac fibroblasts isolated from Ang II-infused ATF3KO mice. p38 phosphorylation significantly decreased in cardiac fibroblasts of ATF3 fl/fl TGCre + mice in comparison with TGCre -mice ( Figure 6K ). These data suggested that ATF3 may inhibit hypertensive remodeling by suppressing Map2K3 expression and subsequent p38 inhibition. We performed additional experiments to obtain direct evidence supporting this notion. First, cardiac myocytes were cocultured with cardiac A, Cardiac fibroblasts from WT and ATF3KO mice were treated Ang II for 48 hours. The expression of α-SMA and collagen I was detected by Western blot. *P<0.05 versus WT CF+Ang II. # P<0.05 versus PBS. B, Cardiac fibroblasts from ATF3KO mice were transfected with lentivirus-medicated Map2K3 shRNA (LV-Map2K3-shRNA) or lentivirus-Control-shRNA (LV-con-shRNA) for 48 hours, and subjected to Ang II for 48 additional hours. The expression of α-SMA and collagen I was detected. *P<0.05 compared with LV-con-shRNA+Ang II. C and D, CM was treated with supernatant from ATF3KO cardiac fibroblasts infected with LV-Map2K3-shRNA or LV-con-shRNA, with or without Ang II. ANP mRNA expression and cardiomyocyte area were evaluated. *P<0.05 versus CM+KO CF+LV-con-shRNA+Ang II. # P<0.05 versus CM+KO CF+PBS. E, Cardiac fibroblasts were transfected with Ad-ATF3 or empty Ad-con adenovirus for 48 hours, and pulsed with Ang II for another 6 hours. Nuclear extracts were isolated and immunoprecipitated with anti-IgG or anti-ATF3 antibody, and immunoblotted with anti-HDAC1 or anti-ATF3. *P<0.05 versus Ad-con transfection. F, Cardiac fibroblast was transfected with Ad-ATF3 or Ad-con for 48 hours and plus with Ang II for 6 hours. ChIP assays were performed with antiacetyl H4 antibody, then Map2K3 binding was assessed. *P<0.05 versus Ad-conin H4AC Ab. Figure 7C and 7D). Given the well-recognized role of TGF-β in ventricular remodeling, and its identification as one of the foremost 3 downregulated pathways after p38 inhibition (RNA-seq analysis, online-only Data Supplement Figure  VIIIC) , as well, we determined the effect of p38 inhibition on Ang II-activated TGF-β signaling in ATF3KO cardiac fibroblasts. qRT-PCR analysis demonstrated the mRNA levels of TGF-β signaling-related genes (including Tgfb2, BMP4, Thbs2, Thbs3, Col1a1, Col3a1, Igf1, Itgb5, and Igfbp5) were significantly upregulated in ATF3-deficient cardiac fibroblasts, and were suppressed after p38 inhibition ( Figure 8A and 8B ). In addition, multiple signaling molecules known to be responsible for TGF-β-mediated fibrosis and cardiac myocyte hypertrophy (including interleukin 6, endothelin-1, fibroblast growth factor 2, and phosphorylated Smad3) were all significantly increased in ATF3-deficient cardiac fibroblasts after Ang II treatment. These effects were abrogated in the setting of p38 inhibition ( Figure 8C through 8G) .
To determine the translational value of our results thus far, we performed cross-species transcriptome analysis of cardiac tissue from 5 HCM patients (onlineonly Data Supplement Table V) and control, and of Ang IIstimulated cardiac fibroblasts pretreated with or without a p38 inhibitor. Hierarchical clustering of the data was performed, yielding 970 upregulated genes and 829 downregulated genes in HCM patient hearts (P<0.05, fold change>1.5) (online-only Data Supplement Figure  IXA) . Pathway analysis identified the 7 most significantly upregulated pathways in HCM, including extracellular matrix-receptor interaction, focal adhesion, regulation of actin cytoskeleton, hypertrophic cardiomyopathy, dilated cardiomyopathy, TGF-β signaling pathway, and arrhythmogenic right ventricular cardiomyopathy (onlineonly Data Supplement Figure IXB) . It is notable that this HCM-specific signature was downregulated in cardiac fibroblasts after p38 inhibitor treatment (online-only Data Supplement Figure IXC and IXD) . Sixty-three DEGs were transcriptionally regulated in the same direction (43 A and B, qRT-PCR analysis of TGF-β signaling-related genes in Ang II-stimulated cardiac fibroblasts isolated from Ang II-infused WT and ATF3KO heart (A), or ATF3KO cardiac fibroblasts with or without p38 inhibitor (B). *P<0.05 compared with WT CFs (A).*P<0.05 compared with ATF3KO CFs+control (B). C, WT and ATF3KO cardiac fibroblasts were stimulated with Ang II or saline for 4 hours. The phosphorylation of smad3 (p-smad3) expression was detected. D, ATF3KO cardiac fibroblasts were pretreated with p38 inhibitor or control for 1 hour, and stimulated with Ang II for 4 hours. The p-smad3 expression was detected. E through G, The levels of IL-6, FGF-2, and Endothlin-1 were assessed by ELISA in WT or ATF3KO cardiac fibroblasts subjected to Ang II stimuli, with or without p38 inhibitor pretreatment. *P<0.05 versus ATF3KO CF+Ang II.
# P<0.05 versus non Ang II treatment. Data from 3 independent experiments. Statistical significance was determined by the unpaired t test (A and B) or by 1-way ANOVA test (C through G). ). Ang II indicates angiotensin II; ANOVA, analysis of variance; ATF3, activating transcription factor 3; ATF3KO, ATF3 knockout; ELISA, enzyme-linked immunosorbent assay; FGF-2, fibroblast growth factor 2; IL-6, interleukin 6; qRT-PCR, quantitative real-time polymerase chain reaction; TGF-β, transforming growth factor-β; and WT, wild type.
DEGs were upregulated and 20 DEGs were downregulated in each of the 2 groups), and 121 DEGs in opposite directions (97 DEGs were upregulated and 24 DEGs were downregulated genes in opposite patterns) after p38 inhibition (online-only Data Supplement Figure IXE) . Moreover, pathway analysis revealed that downregulation of 97 overlapped DEGs after p38 inhibition was enriched in the 7 signature HCM pathways (online-only Data Supplement Figure IXF through IXH) .
DISCUSSION
We have made 2 novel findings in this study. First, by utilizing discovery-driven/nonbiased approaches, we have demonstrated that hypertensive stimuli selectively upregulated ATF3 expression in cardiac fibroblast cells, not in cardiac myocytes, given recent recognition that the same molecule expressed in different cell types may have different, or even opposite, impacts on global organ function. 26, 27 Second, cardiac fibroblast-specific ATF3 protects against hypertensive remodeling and heart failure by suppressing Map2K3 transcription and p38 signaling.
Although it is well recognized that ATF3 is encoded by an immediate early gene with quickly upregulated expression in response to various stress, 28 the physiological/pathological consequence of ATF3 upregulation remains largely unknown. 29 Recent studies demonstrate that cardiac ATF3 expression is increased in response to pathological stress. 30, 31 However, the currently available information regarding the functional importance of ATF3 in ventricular remodeling is limited and controversial. Specifically, Zhou et al 31 first reported that global ATF3 deficiency promotes cardiac hypertrophy and fibrosis in pressure overload-induced heart failure, suggesting a cardioprotective function of ATF3. However, another study published 2 years later reported an exactly opposite effect, noting that cardiac myocyte-specific ATF3 overexpression promotes ventricular hypertrophy and fibrosis. 32 Our study demonstrated that ATF3 expression is selectively increased in cardiac fibroblasts in both Ang II infusion-induced and TAC-induced hypertensive remodeling models, challenging the pathological relevance and subsequent conclusions concerning cardiac myocyte-specific ATF3 overexpression. To obtain the most reliable evidence possible to clarify the origin of ATF3 pertaining to cardiac remodeling, we used 3 separate approaches. We first used a loss-of-function approach, demonstrating significantly enhanced Ang II-induced cardiac remodeling in ATF3KO mice. We then established a miRNA-aided ATF3-carrying lentivirus system preventing cardiomyocyte ATF3 overexpression, demonstrating that noncardiac myocyte ATF3 overexpression rescued the profibrotic/hypertrophic ATF3KO phenotype. Most important, we generated a tamoxifen-inducing cardiac fibroblast cell-specific ATF3 transgenic mouse line, demonstrating that cardiac fibroblast-specific ATF3 overexpression attenuated Ang II-induced cardiac remodeling and improved cardiac function. Collectively, we have provided clear evidence that cardiac fibroblast expression of ATF3 is a self-protective mechanism that counteracts harmful cardiac TFs, protecting the heart against hypertensive remodeling. Our results not only provide a likely explanation regarding the recently reported opposite effects of ATF3 in cardiac remodeling, 31, 32 but also significantly aid our understanding of the yin and yang balance underlying hypertensive cardiac remodeling regulation.
Cardiac fibroblasts have central and dynamic roles in modulating cardiac function. 33 During physiological conditions, cardiac fibroblasts provide the mechanical scaffold for cardiac myocytes and coordinate cardiac pump function. Under pathological conditions, cardiac fibroblasts are preferentially activated by stress signals. 34, 35 Activated cardiac fibroblasts produce an array of biologically active molecules, including growth factors and cytokines, which may either contribute to or protect against cardiac myocyte injury via paracrine-mediated cell-cell communications. 36 However, the precise molecular mechanisms rendering cardiac fibroblasts more sensitive to stress (eg, selective ATF3 overexpression in response to Ang II and TAC stimuli observed in the present study) remain unclear, and warrant direct investigation.
Second, we combined both in vitro and in vivo models, performed bioinformatics analysis, and integrated transcriptomics in ATF3-depleted fibroblasts and ChIP-seq for ATF3 binding sites. We identified Map2K3 as a novel ATF3 target. It is interesting to note that ATF3-deficient mice exhibited increased Map2K3 expression, whereas ATF3 overexpression inhibited Map2K3 expression. Contrary to expectations, given its nomenclature, binding of the Map2K3 promoter by ATF3 suppresses, not activates, Map2K3 mRNA expression. Functionally, inhibition of Map2K3 signaling ameliorated the remodeling phenotype observed in ATF3-deficient animals, indicating that augmented cardiac fibroblast ATF3 expression in response to hypertensive stress impedes Map2K3 expression. Given the well-recognized profibrotic/hypertrophic effect of Map2K3 signaling, 37, 38 transcriptional suppression of Map2K3 expression is a novel mechanism by which ATF3 functionally protects against hypertensive remodeling.
When coexpressed with heterodimeric partners, or expressed as an alternative splicing product, ATF3 activates transcription. However, as a homodimer, native ATF3 represses transcription. 39 The molecular mechanisms responsible for such contradictory function remain unidentified. Gene expression is regulated at multiple levels, including epigenetic regulation by DNA methylation and histone acetylation. In particular, HDAC-mediated histone deacetylation tightens chromatin structure and inhibits gene expression. In this regard, we demonstrate for the first time that ATF3 not only directly binds the Map2K3 promoter, but also recruits HDAC1. More important, the levels of Map2K3 promoter-bound histone acetylation in cardiac fibroblasts significantly increased after Ang II treatment. ATF3 overexpression blocked the effects of Ang II, and significantly increased Map2K3 promoter-bound histone acetylation levels. To the best of our knowledge, this is the first study providing an explanation for ATF3-mediated suppression, not activation, of Map2K3 gene transcription. Moreover, our current work further underscores the important and unique regulatory function of ATF3, because it activates select target genes but represses others, depending on both promoter and cellular context.
We demonstrated that p38, not JNK or ERK, is activated in ATK3KO cardiac fibroblasts. Moreover, in a fashion similar to Map2K3 inhibition, p38 inhibition ameliorated the exacerbated remodeling phenotype observed in ATF3-deficient cells. These results indicate that p38 activation in cardiac fibroblasts is responsible for Map2K3-mediated profibrotic/hypertrophic effects in ATF3KO animals. These observations are supported by a previous study demonstrating that tumor necrosis factor-α administration to cardiac fibroblasts promotes Map2K3 expression, and predominantly activates p38-mediated inflammatory response. 40 It is interesting to note that pharmacological inhibition of p38 is cardioprotective in diabetic mice or mice subjected to myocardial ischemia. 41, 42 However, cardiac myocyte-specific attenuation of p38α results in enhanced cardiac myocyte hypertrophy, apoptosis, and cardiac fibrosis. 43 Therefore, the origin of p38 (from cardiac myocyte versus cardiac fibroblast) bears influence on cardiac remodeling and overall cardiac function. This very phenomenon plausibly explains the discrepancy between cardiomyocyteexpressed ATF3 and cardiac fibroblast-expressed ATF3 concerning their hypertrophic/profibrotic (as previously reported 31, 32 ) and antihypertrophic/antifibrotic effects (as observed in our study).
In summary, we have provided the first evidence that cardiac fibroblast upregulation of ATF3 is a compensatory cardiac protective mechanism activated by hypertensive stimuli. Mechanistically, we demonstrated for the first time that ATF3 binds to the Map2K3 promotor, recruits HDAC1, and results in histone deacetylation, blocking Map2K3 expression and subsequent p38-TGF-β signaling. Our data suggest positive modulation of cardiac fibroblast ATF3, a hub of the cellular adaptiveresponse network, may represent a novel therapeutic approach against hypertensive cardiac remodeling.
